MedTrace Logo

RV568 - Viral Challenge With RSV

NCT01230645 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-02-11

No results posted yet for this study

Summary

RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 is effective in reducing the inflammation caused by viral infections such as RSV (respiratory syncytial virus).

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

RV568

RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)

DRUG

Placebo

Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)

Sponsors & Collaborators

  • Respivert Ltd

    lead INDUSTRY

Principal Investigators

  • Anthony Gilbert, MD · Retroscreen Virology Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01230645 on ClinicalTrials.gov